Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC: Intrathecal Pemetrexed for NSCLC with Leptomeningeal Metastases
NCT06440954Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Primary endpoint: Intracranial progression-free survival at 36 months. Started May 2024; status: recruiting.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06440954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06440954.